Adicet announces appointment of katie peng to the board of directors

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced the appointment of katie peng to its board of directors. “we are delighted to welcome katie to our board of directors,” said chen schor, president and chief executive officer of adicet bio. “her proven success as a commercial leader in both the u.s. and globally will be particularly.
ACET Ratings Summary
ACET Quant Ranking